These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33123561)

  • 1. Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations.
    Jauhiainen A; Scheepers LEJM; Fuhlbrigge AL; Harrison T; Zangrilli J; Garcia Gil E; Gustafson P; Fagerås M; Da Silva CA
    ERJ Open Res; 2020 Oct; 6(4):. PubMed ID: 33123561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of CompEx in eosinophilic patients with severe, uncontrolled asthma on benralizumab.
    Bolton C; Harrison T; Lugogo N; Fuhlbrigge A; Hirsch I; Bengtsson T; Peterson S; Sidaway M; Garcia Gil E; Fagerås M; Da Silva CA
    ERJ Open Res; 2024 Mar; 10(2):. PubMed ID: 38500798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials.
    Fuhlbrigge AL; Bengtsson T; Peterson S; Jauhiainen A; Eriksson G; Da Silva CA; Johnson A; Sethi T; Locantore N; Tal-Singer R; Fagerås M
    Lancet Respir Med; 2017 Jul; 5(7):577-590. PubMed ID: 28583396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
    FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
    Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma.
    Jorup C; Lythgoe D; Bisgaard H
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29301922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma.
    Murphy KR; Uryniak T; Martin UJ; Zangrilli J
    Drugs R D; 2012 Mar; 12(1):9-14. PubMed ID: 22329608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma.
    Reddel HK; O'Byrne PM; FitzGerald JM; Barnes PJ; Zheng J; Ivanov S; Lamarca R; Puu M; Alagappan VKT; Bateman ED
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3069-3077.e6. PubMed ID: 33895362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positioning As-needed Budesonide-Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2.
    Bateman ED; O'Byrne PM; FitzGerald JM; Barnes PJ; Zheng J; Lamarca R; Puu M; Parikh H; Alagappan V; Reddel HK
    Ann Am Thorac Soc; 2021 Dec; 18(12):2007-2017. PubMed ID: 33979557
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
    O'Byrne PM; FitzGerald JM; Bateman ED; Barnes PJ; Zheng J; Gustafson P; Lamarca R; Puu M; Keen C; Alagappan VKT; Reddel HK
    Lancet Respir Med; 2021 Feb; 9(2):149-158. PubMed ID: 33010810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials.
    O'Byrne PM; FitzGerald JM; Zhong N; Bateman E; Barnes PJ; Keen C; Almqvist G; Pemberton K; Jorup C; Ivanov S; Reddel HK
    Trials; 2017 Jan; 18(1):12. PubMed ID: 28069068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.
    Pavord ID; Holliday M; Reddel HK; Braithwaite I; Ebmeier S; Hancox RJ; Harrison T; Houghton C; Oldfield K; Papi A; Williams M; Weatherall M; Beasley R;
    Lancet Respir Med; 2020 Jul; 8(7):671-680. PubMed ID: 32171064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
    Hardy J; Baggott C; Fingleton J; Reddel HK; Hancox RJ; Harwood M; Corin A; Sparks J; Hall D; Sabbagh D; Mane S; Vohlidkova A; Martindale J; Williams M; Shirtcliffe P; Holliday M; Weatherall M; Beasley R;
    Lancet; 2019 Sep; 394(10202):919-928. PubMed ID: 31451207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
    Menzella F; Bargagli E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Caruso C; Centanni S; D'Amato M; Del Giacco S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Simoni L; Ori A; Boarino S; Vitiello G; Altieri E; Canonica GW
    Respir Res; 2022 Feb; 23(1):36. PubMed ID: 35183167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone.
    Peters SP; Bleecker ER; Canonica GW; Park YB; Ramirez R; Hollis S; Fjallbrant H; Jorup C; Martin UJ
    N Engl J Med; 2016 Sep; 375(9):850-60. PubMed ID: 27579635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.
    Rabe KF; Atienza T; Magyar P; Larsson P; Jorup C; Lalloo UG
    Lancet; 2006 Aug; 368(9537):744-53. PubMed ID: 16935685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.